PharmaCorp Rx Income Statement

Financials in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	20.89	5.79	-	-	-
Revenue Growth (YoY)	260.57%	-	-	-	-
Cost of Revenue	12.6	3.61	-	-	-
Gross Profit	8.3	2.18	-	-	-
Selling, General & Admin	8.19	3.2	0.58	0.18	0.08
Operating Expenses	9.54	3.77	0.58	0.56	0.08
Operating Income	-1.24	-1.59	-0.58	-0.56	-0.08
Interest Expense	-0.06	-0.01	-	-	-
Interest & Investment Income	0.29	0.38	0.11	0.05	0
Other Non Operating Income (Expenses)	0.16	0.06	-	-	-
Pretax Income	-0.84	-1.16	-0.47	-0.52	-0.08
Income Tax Expense	0.59	-0.11	-	-	-
Earnings From Continuing Operations	-1.42	-1.05	-0.47	-0.52	-0.08
Minority Interest in Earnings	-0.06	0.04	-	-	-
Net Income	-1.48	-1.01	-0.47	-0.52	-0.08
Net Income to Common	-1.48	-1.01	-0.47	-0.52	-0.08
Shares Outstanding (Basic)	125	82	20	20	16
Shares Outstanding (Diluted)	125	82	20	20	16
Shares Change (YoY)	53.12%	303.02%	1.39%	23.69%	-
EPS (Basic)	-0.01	-0.01	-0.02	-0.03	-
EPS (Diluted)	-0.01	-0.01	-0.02	-0.03	-
Free Cash Flow	1.92	0.12	-0.52	-0.12	0
Free Cash Flow Per Share	0.01	0.00	-0.03	-0.01	-
Gross Margin	39.72%	37.69%	-	-	-
Operating Margin	-5.92%	-27.41%	-	-	-
Profit Margin	-7.09%	-17.48%	-	-	-
Free Cash Flow Margin	9.18%	2.04%	-	-	-
EBITDA	-0.41	-1.35	-	-	-
EBITDA Margin	-1.98%	-23.23%	-	-	-
D&A For EBITDA	0.82	0.24	-	-	-
EBIT	-1.24	-1.59	-0.58	-0.56	-0.08
EBIT Margin	-5.92%	-27.41%	-	-	-
Revenue as Reported	-	-	-	0.05	0

Source: S&P Global Market Intelligence. Standard template. Financial Sources.